Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

Breast Cancer Research and Treatment

Volumn 120, Issue 1, 2010, Pages 1-7

  Moelans, Cathy B ^a   De Weger, Roel A ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; CEP17; HER2; MLPA; Polysomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AMPLICON; BREAST CARCINOMA; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME ANALYSIS; GENETIC ASSOCIATION; HUMAN; IN SITU HYBRIDIZATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; REVIEW;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 74849138869     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0539-2     Document Type: Review

References (27)

1. T Akiyama C Sudo H Ogawara K Toyoshima T Yamamoto 1986 The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1644 1646 10.1126/science.3012781 1:CAS:528: DyaL28XkvFahu7o%3D 3012781 (Pubitemid 16095607)
2. NC Popescu CR King MH Kraus 1989 Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32 Genomics 4 362 366 10.1016/0888-7543(89)90343-1 1:CAS:528:DyaL1MXit1Knsb8%3D 2565881
3. H Joensuu PL Kellokumpu-Lehtinen P Bono T Alanko V Kataja R Asola T Utriainen R Kokko A Hemminki M Tarkkanen T Turpeenniemi-Hujanen S Jyrkkio M Flander L Helle S Ingalsuo K Johansson AS Jaaskelainen M Pajunen M Rauhala J Kaleva-Kerola T Salminen M Leinonen I Elomaa J Isola 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 10.1056/NEJMoa053028 1:CAS:528:DC%2BD28Xhsl2gsrY%3D 16495393 (Pubitemid 43290919)
4. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
5. CA Hudis 2007 Trastuzumab, mechanism of action and use in clinical practice N Engl J Med 357 39 51 10.1056/NEJMra043186 1:CAS:528: DC%2BD2sXnsVygu7s%3D 17611206 (Pubitemid 47026733)
6. I Vanden Bempt LP Van M Drijkoningen P Neven A Smeets MR Christiaens R Paridaens C De Wolf-Peeters 2008 Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 4869 4874 10.1200/JCO.2007.13.4296 10.1200/JCO.2007.13.4296
7. E Downs-Kelly BJ Yoder M Stoler RR Tubbs M Skacel T Grogan P Roche DG Hicks 2005 The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study Am J Surg Pathol 29 1221 1227 10.1097/01.pas.0000165528.78945.95 16096413 (Pubitemid 41232996)
8. CL Hyun HE Lee KS Kim SW Kim JH Kim G Choe SY Park 2008 The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer J Clin Pathol 61 317 321 10.1136/jcp.2007.050336 10.1136/jcp.2007.050336 1:STN:280: DC%2BD1c7ksVSmsA%3D%3D 17761736 (Pubitemid 351354237)
9. Bartlett JM, Desmedt C, Munro A, O'Malley FP, Larsimont D, Di Leo A, Cameron DA, Isola J, Shepherd L, Twelves CJ, Pritchard KI (2009) Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines? Cancer Res 69(Suppl. 2):11
10. F Courjal C Theillet 1997 Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification Cancer Res 57 4368 4377 1:CAS:528:DyaK2sXmsFCgsrg%3D 9331100
11. F Forozan EH Mahlamaki O Monni Y Chen R Veldman Y Jiang GC Gooden SP Ethier A Kallioniemi OP Kallioniemi 2000 Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data Cancer Res 60 4519 4525 1:CAS:528:DC%2BD3cXmsVahsrc%3D 10969801
12. J Hicks A Krasnitz B Lakshmi NE Navin M Riggs E Leibu D Esposito J Alexander J Troge V Grubor S Yoon M Wigler K Ye AL Borresen-Dale B Naume E Schlicting L Norton T Hagerstrom L Skoog G Auer S Maner P Lundin A Zetterberg 2006 Novel patterns of genome rearrangement and their association with survival in breast cancer Genome Res 16 1465 1479 10.1101/gr.5460106 10.1101/gr.5460106 1:CAS:528:DC%2BD28XhtlWgsrbE 17142309 (Pubitemid 44878486)
13. B Orsetti M Nugoli N Cervera L Lasorsa P Chuchana L Ursule C Nguyen R Redon MS du C Rodriguez C Theillet 2004 Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes Cancer Res 64 6453 6460 10.1158/0008-5472.CAN-04-0756 1:CAS:528:DC%2BD2cXnsFOltLc%3D 15374954 (Pubitemid 39297900)
14. F Andre B Job P Dessen A Tordai S Michiels C Liedtke C Richon K Yan B Wang G Vassal S Delaloge GN Hortobagyi WF Symmans V Lazar L Pusztai 2009 Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array Clin Cancer Res 15 441 451 10.1158/1078-0432.CCR-08-1791 10.1158/1078-0432.CCR-08-1791 1:CAS:528: DC%2BD1MXlvFeksA%3D%3D 19147748
15. JR Pollack T Sorlie CM Perou CA Rees SS Jeffrey PE Lonning R Tibshirani D Botstein AL Borresen-Dale PO Brown 2002 Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors Proc Natl Acad Sci USA 99 12963 12968 10.1073/pnas.162471999 10.1073/pnas.162471999 1:CAS:528:DC%2BD38XnvFGht7c%3D 12297621
16. E Arriola C Marchio DS Tan SC Drury MB Lambros R Natrajan SM Rodriguez-Pinilla A Mackay N Tamber K Fenwick C Jones M Dowsett A Ashworth JS Reis-Filho 2008 Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines Lab Invest 88 491 503 10.1038/labinvest.2008.19 10.1038/labinvest.2008.19 1:CAS:528:DC%2BD1cXltVGrs7k%3D 18332872 (Pubitemid 351581454)
17. JP Schouten CJ McElgunn R Waaijer D Zwijnenburg F Diepvens G Pals 2002 Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification Nucleic Acids Res 30 e57 10.1093/nar/gnf056 12060695
18. CB Moelans RA de Weger MT van Blokland C Ezendam S Elshof MG Tilanus PJ van Diest 2009 HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization Cell Oncol 31 1 10 1:CAS:528:DC%2BD1cXhsFSmt7bK 19096145
19. Slamon D, Eiermann W, Robert N (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2-positive early breast cancer patients: BCIRG006 study.94:S5, 2005 (suppl. 1; abstr 1)
20. JS Coon E Marcus S Gupta-Burt S Seelig K Jacobson S Chen V Renta G Fronda HD Preisler 2002 Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 1061 1067 1:CAS:528:DC%2BD38XjsF2ltr8%3D 11948114
21. PJ van Diest 2002 No consent should be needed for using leftover body material for scientific purposes BMJ 325 648 651 10.1136/bmj.325.7365.648 12242180
22. J Coffa MA van de Wiel B Diosdado B Carvalho J Schouten GA Meijer 2008 MLPAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data Cell Oncol 30 323 335 1:CAS:528:DC%2BD1cXnvFShsLk%3D 18607067
23. P Kauraniemi T Kuukasjarvi G Sauter A Kallioniemi 2003 Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer Am J Pathol 163 1979 1984 1:CAS:528:DC%2BD3sXpsVWltbk%3D 14578197
24. M Hofmann O Stoss T Gaiser H Kneitz P Heinmoller T Gutjahr M Kaufmann T Henkel J Ruschoff 2008 Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J Clin Pathol 61 89 94 10.1136/jcp.2006.043562 10.1136/jcp.2006.043562 1:CAS:528:DC%2BD1cXitlWlsbg%3D 17412870 (Pubitemid 351158232)
25. CB Moelans RA de Weger C Ezendam PJ van Diest 2009 HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification: influence of manual- and laser microdissection BMC Cancer 9 4 10.1186/1471-2407-9-4 10.1186/1471-2407-9-4 19123950
26. Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR (2009) Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. doi: 10.1038/modpathol.2009.78
27. C Marchio MB Lambros P Gugliotta LV Di Cantogno C Botta B Pasini DS Tan A Mackay K Fenwick N Tamber G Bussolati A Ashworth JS Reis-Filho A Sapino 2009 Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis J Pathol 219 16 24 10.1002/path.2574 10.1002/path.2574 1:CAS:528:DC%2BD1MXhtFGgs7%2FI 19670217